Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Q4 FY2018 Earnings Presentation
8 slides from Sonoma Pharmaceuticals's earnings presentation, Jun 13, 2018
Slide 1: Sonoma Pharmaceuticals Fourth Quarter FY2018 Results
NASDAQ: SNOA SONOMA PHARMACEUTICALS FOURTH QUARTER FY2018 RESULTS June 13, 2018
Slide 2: Agenda
NASDAQ: SNOA Page Agenda 2 Welcome / Introduction March 31, 2018 Highlights Financial Review Q+A Jim Schutz Bob Miller
Slide 3: Forward-Looking Statement
NASDAQ: SNOA Page Forward - Looking Statement Except for historical information herein, matters set forth in this presentation are forward - looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial a
Slide 4: Results from the Year Ending Mar 2018
NASDAQ: SNOA Page Results from the Year Ending 31 Mar 2018 4 Revenue = $ 16.7M +30 % over FY 2017 Gross U.S. dermatology revenue +85% Net. U.S. dermatology revenue + 40% International revenue + 36% U.S. product revenue + 27% Cash on Hand 3/31/18 = $10.1M
Slide 5: Milestones Achieved in the year ended Mar 2018
NASDAQ: SNOA Page Milestones Achieved in the year ended 31 Mar 2018 March 2018 – FDA approval to add antimicrobial indication to Acuicyn January 2018 - Three UAE approvals for blepharitis, chronic rhinosinusitis and oral care Nov + Dec 2017 - Three FDA approvals to expand indications to add an
Slide 6: U.SK/NC Group and SNOA Partnership
NASDAQ: SNOA Page U.SK, a division of NC Group: • Largest pharma company in Brazil with more than $3B in annual revenues • 3 rd largest pharma company in Latin America • 7,000 employees • 70+ dermatology sales reps covering 7,000 dermatologists in Brazil Brazil: 3 rd largest market for beauty produc
Slide 7: Comparison of March YTD 2018 to March YTD 2017
Comparison of March YTD 2018 to March YTD 2017 7 * dollars in thousands, unaudited Year Ended Year Ended March 31, 2017 ®¬ - Mar - 18 Amount $ Change ¸ Total net revenue $ 16,658 $12,825 $ 3,833 Product revenue $ 15,663 $11,957 $ 3,706 31 International revenue $ 7,291 $5,377 $1,914 36 US pr
Slide 8: Comparison of QE March 2018 to QE March 2017
Comparison of QE March 2018 to QE March 2017 8 * dollars in thousands, unaudited QTR Ended QTR Ended March 31, 2017 ®¬ - Mar - 18 Amount $ Change ¸ Total net revenue $3,655 $4,029 - $374 Product revenue $3,269 $3,799 - $530 International product revenue $1,907 $1,960 - $53 US reve
Sonoma Pharmaceuticals — Q4 FY2018 Earnings Presentation on 6ix